Astellas Pharma Hits Day High with Strong 3.35% Intraday Surge

Astellas Pharma, Inc. has experienced a notable increase of 3.35% on April 15, 2026, reaching an intraday high of JPY 2,605.50. This performance stands out against the Japan Nikkei 225, which rose by only 0.44% on the same day. Over the past month, Astellas has shown a robust growth of 10.33%, outperforming the Nikkei's 8.02% increase. In terms of annual performance, Astellas Pharma has delivered an impressive return of 94.88%, significantly exceeding the Nikkei 225's 69.65%. Year-to-date, the stock has risen by 24.49%, compared to the Nikkei's 15.48%. Despite a slight decline of 0.71% over the past week, the company's long-term performance remains strong, with a three-year return of 33.75% and a five-year return of 57.57%. Astellas Pharma's financial metrics reflect a solid market position, highlighted by a high return on equity (ROE) of 7.74% and a healthy EBIT to interest ratio of 42.73. The company also reported a significant growth in net sales of 10.4%, showcasing its operational strength within the pharmaceuticals and biotechnology sector.